Alzheimer Disease (AD)
Phase 1Protein / enzyme
Alzheimer Disease (AD) is one of 55 biologic programs targeting Cognitive impairment. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
72 competitors in Cognitive Impairment
#DrugCompanyPhaseTrials
1Aricept
EisaiApproved
Exelon
NovartisApproved
Ritalin
NovartisApproved
Aldactone
PfizerApproved
Cymbalta
Jazz PharmaceuticalsApproved
Avandia
Jazz PharmaceuticalsApproved
Epidiolex
Jazz PharmaceuticalsApproved
Glucophage
EMD SeronoApproved
Lithobid
SSolvay Pharmaceuticals
Approved
Coumadin
AAbbott
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Alzheimer Disease (AD). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 1[1]
- Company
- KKeymed Biosciences Co.Ltd